Glenmark Generics plunges on recalling Montelukast Sodium tablets from US market

19 Mar 2013 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs 495.00, down by 4.65 points or 0.93% from its previous closing of Rs 499.65 on the BSE.

The scrip opened at Rs 497.00 and has touched a high and low of Rs 498.00 and Rs 488.10 respectively. So far 16971 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 550.80 on 09-Jan-2013 and a 52 week low of Rs 296.00 on 23-Mar-2012.

Last one week high and low of the scrip stood at Rs 503.25 and Rs 483.30 respectively. The current market cap of the company is Rs 13353.07 crore.

The promoters holding in the company stood at 48.32% while Institutions and Non-Institutions held 40.01% and 11.67% respectively.

Glenmark Generics is recalling multiple lots of Montelukast Sodium tablets (10 mg), from the US market due to odor complaints from US Food and Drug Administration. The tablet is used in treatment of chronic asthma and prophylaxis. The entity will be withdrawing as many as 591,972 bottles of Montelukast Sodium tablets of both 30 and 90-count from the market.

Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.

Glenmark Pharma Share Price

1592.90 -33.65 (-2.07%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.